1）Bucher HC, Griffith LE, Guyatt GH.Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999;19:187-95.

2）The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.

3）Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4444 patients with coronary　heart disease:the Scandinavian Simvastatin Survival Study (4S).Lancet1994;344:1383-9.

4）Sacks FM, et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001.

5）The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.N Engl J Med 1998;339:1349.

6）Ballantyne CM, Herd JA, Dunn JK, Jones PH, Farmer JA, Gotto AM Jr. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol 1997;354-61.

7）Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes(1).N Engl J Med;1992:242-50.

8）Shepherd J, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.

9）Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.

10）Egashira K, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients withhypercholesterolemia. Circulation 1994;89:2519-24.

11）Anderson TJ,et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332:488-93.

12）Stephens NG, et al. Randomised controlled trial of vitamin E in patients with coronary disease:cambridge Heart Antioxidant Study. Lancet 1996;347:781.

13）Tardif.JC, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997;337:365.

14）Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P,　Koskinen P, Manninen V, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia.

15）Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987 ;317:1237-45.

16）Ericsson CG, Hamsten A, Nilsson J , Grip L, Svane B, Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet1996;347:849-53.

17）Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998; 641-8.

18）Steiner G.Lipid intervention trials in diabetes. Diabetes Care Suppl 2000; 2:B49-53.

19）Rubins HB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.